Turkovac
Turkovac[1] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.
Clinical trials[edit]
In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[2]
In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[3]
In June 2021, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[4] As of 2023 phase III trials continue.[5]
Authorization[edit]
On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[6] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[7]